Contributors
Mohamad‐Gabriel Alameh(Children's Hospital of Philadelphia), Jiehua Zhou(Wuhan University), Marcin Kortylewski(City of Hope), Krystal C. Johnson(Southwestern Medical Center), Gabriel Lopez‐Berestein(The University of Texas MD Anderson Cancer Center), Yu‐Lin Su(National Tsing Hua University), Marice Alcantara(City Of Hope National Medical Center), Thomas M. Rupp, Jessica Alluin(City of Hope), Jon Voutila, Cristian Rodriguez-Aguayo, Daniel J. Schneider, Chunsong Yu, Dan Peer(Tel Aviv University), Bruce A. Sullenger(Duke University), Dalit Landesman‐Milo, Kevin Holm(City of Hope), Rachel Ostroff(SomaLogic (United States)), David R. Corey(Southwestern Medical Center), John J. Rossi(City of Hope), Selin Öncül, Edo Kon(Tel Aviv University), Nagy Habib(Hammersmith Hospital), Samantha T. Johnson(Southwestern Medical Center), Drew Weissman(California University of Pennsylvania), Marc Lemaître, Daniel Rossi(SomaLogic (United States)), Haixiang Yu, Amy D. Gelinas(SomaLogic (United States)), James W. Frederiksen(Duke Medical Center), Patricia Soblechero‐Martín, Preston Williams, Paola Amero(The University of Texas MD Anderson Cancer Center), John C. Rohloff, Virginia Arechavala‐Gomeza(Ikerbasque), Niels Dammes(Tel Aviv University), Anil K. Sood(The University of Texas MD Anderson Cancer Center), Zhuoran Zhang(Tianjin Medical University General Hospital), Sean A. Lynch, Inbal Hazan‐Halevy(Tel Aviv University), Daniel W. Drolet(Howard Hughes Medical Institute), George A. Calin(The University of Texas MD Anderson Cancer Center), Christopher Lincoln, Nebojša Janjić(Nivalis Therapeutics (United States)), H. Cramer, Min-Sun Song
Cited by 0
Related Papers
mRNA vaccines — a new era in vaccinology
|Nature Reviews Drug Discovery|2018|4.4k
Monitoring dopants by Raman scattering in an electrochemically top-gated graphene transistor
|Nature Nanotechnology|2008|3.6k
MicroRNA Expression Profiles Associated With Prognosis and Therapeutic Outcome in Colon Adenocarcinoma
|JAMA|2008|1.6k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k